Empirical treatments for microbial infections predate the discovery of bacteria by thousands of years, with ancient civilizations in Egypt and elsewhere applying moldy bread and medicinal plant extracts to infected wounds.¹² The scientific foundation for antimicrobial therapy emerged in the late nineteenth and early twentieth centuries alongside the germ theory of disease. German physician Paul Ehrlich observed that certain chemical dyes selectively stained bacterial cells while leaving surrounding animal tissue untouched, leading him to propose the concept of a "magic bullet" capable of targeting pathogens specifically inside a human host. After screening more than 600 arsenic-based compounds in his laboratory, Ehrlich and his colleagues identified the 606th compound, arsphenamine, in 1909.¹³ Marketed as Salvarsan, it became the first effective chemotherapeutic treatment for syphilis. In the 1930s, German pathologist Gerhard Domagk discovered that a red dye derivative called Prontosil protected mice and humans against streptococcal infections, introducing the sulfonamides, or sulfa drugs, as the first broadly applicable synthetic antibacterials.

The transition to natural microbial products began in September 1928, when Scottish bacteriologist Alexander Fleming returned from a holiday in Suffolk to his laboratory in London and noticed that an uncovered culture plate of Staphylococcus bacteria had been contaminated by a mold, Penicillium notatum (later reclassified under Penicillium chrysogenum). Around the fungal colonies, the bacterial cells had undergone lysis, creating clear zones of inhibition. Fleming isolated the mold and demonstrated that its broth filtrate, which he named penicillin, inhibited bacterial growth even when diluted 800 times. Because the compound was chemically unstable and difficult to purify in therapeutic quantities, clinical development stalled for over a decade.¹⁴ In 1939, at the University of Oxford, Australian pathologist Howard Florey and German-born biochemist Ernst Chain, alongside biochemist Norman Heatley, assembled a team to isolate and concentrate the active substance.¹⁵¹⁶ In May 1940, they demonstrated that purified penicillin saved mice infected with lethal doses of Streptococcus, publishing their findings in The Lancet in August 1940. Human trials began in February 1941 on an Oxford policeman suffering from severe systemic abscesses; although the patient initially rallied, the limited supply of purified drug was exhausted, and he subsequently died.

Because British pharmaceutical facilities were heavily burdened by World War II, Florey and Heatley traveled to the United States in June 1941 to secure industrial assistance. Working with the United States Department of Agriculture laboratory in Peoria, Illinois, researchers replaced surface-culture flasks with deep-tank submerged fermentation technologies that aerated and agitated the mold in massive vats, while laboratory assistant Mary Hunt identified a high-yielding strain of mold growing on a cantaloupe. By 1944 and 1945, American pharmaceutical manufacturers were producing penicillin on an industrial scale sufficient to treat Allied soldiers and civilian populations.¹⁷ Meanwhile, at Rutgers University, Ukrainian-American soil microbiologist Selman Waksman established systematic screening protocols to test soil-dwelling actinomycetes—particularly bacteria of the genus Streptomyces—for antagonistic activity against pathogens.¹⁸ Waksman, who coined the noun "antibiotic" in 1941 to describe small molecules produced by microbes that inhibit other microbes, oversaw the discovery of more than 20 natural antibacterial substances. Among these was streptomycin, isolated in 1944, which became the first effective cure for Mycobacterium tuberculosis. The period between 1945 and 1955 ushered in the "golden age" of antibiotic discovery, yielding foundational classes such as chloramphenicol, tetracyclines, macrolides, and glycopeptides.¹⁹

Antibiotics are categorized by their pharmacological mode of effect on bacterial populations, their spectrum of antimicrobial activity, their chemical structure, and their route of administration. When classified by cellular outcome, agents are divided into bactericidal drugs, which kill bacteria directly, and bacteriostatic drugs, which arrest bacterial division and growth so that the host's immune system can eliminate the remaining infection.²⁰ A subset of bactericidal medications that actively dissolve the structural integrity of the cell envelope are further described as bacteriolytic. In practice, the distinction between bactericidal and bacteriostatic activity is not absolute; certain bacteriostatic classes can kill specific bacterial species at high concentrations or in particular tissues.

Classification by spectrum of activity reflects the diversity of bacterial groups susceptible to a given compound, which largely depends on whether the drug can penetrate the outer structure of the target cell. Bacteria are broadly divided by the Gram stain technique into Gram-positive species, which possess a thick outer layer of peptidoglycan, and Gram-negative species, which feature a thinner peptidoglycan layer shielded by an outer lipid membrane that restricts the entry of many molecules. Narrow-spectrum antibiotics act selectively against a single species or a restricted group of bacteria; for example, isoniazid is active specifically against Mycobacterium tuberculosis, while glycopeptides such as vancomycin target solely Gram-positive bacteria. Broad-spectrum antibiotics—including fluoroquinolones, tetracyclines, and carbapenems—are effective against a wide range of both Gram-positive and Gram-negative pathogens. Clinicians rely on broad-spectrum agents for empirical therapy when a patient presents with a severe infection and the causative organism has not yet been identified, transitioning to narrow-spectrum drugs once laboratory susceptibility testing—such as the Kirby-Bauer disk diffusion method—confirms the exact pathogen.

To achieve selective toxicity without damaging human tissues, antibiotics target cellular machinery and biochemical pathways that are unique to prokaryotes or structurally distinct from their eukaryotic counterparts. The primary mechanisms of action encompass the inhibition of cell wall synthesis, disruption of the plasma membrane, inhibition of protein synthesis, interference with nucleic acid synthesis, and blockade of essential metabolic pathways.

In clinical medicine, antibiotics are administered both therapeutically to eradicate active bacterial infections and prophylactically to prevent infections in high-risk scenarios, such as prior to orthopedic or abdominal surgeries, in patients with compromised immune systems, or following exposure to certain contagious pathogens. The route of administration is determined by the severity and location of the infection as well as the pharmacokinetic properties of the drug. Mild to moderate community-acquired infections, such as uncomplicated urinary tract or respiratory infections, are typically treated with oral formulations.²⁴ Deep-seated, systemic, or life-threatening conditions—such as bacterial meningitis, endocarditis, sepsis, or complicated pyelonephritis—require intravenous or intramuscular administration to achieve rapid, high concentrations of the drug in the bloodstream and affected tissues.²⁵²⁶²⁷ Localized infections of the skin, eyes, or ears are frequently managed with topical ointments or drops.

Although antibiotics are engineered to spare eukaryotic cells, their administration carries the risk of adverse drug reactions and physiological side effects. Hypersensitivity and allergic reactions are among the most common complications, particularly with penicillins and cephalosporins, ranging from mild maculopapular skin rashes to life-threatening anaphylaxis and hemolytic anemia. Direct organ and tissue toxicities vary by chemical class; penicillins can induce interstitial nephritis, while certain second- and third-generation cephalosporins—such as cefoxitin, cefaclor, and cefotetan—can provoke a disulfiram-like reaction when consumed alongside alcohol.

A major systemic complication of antibiotic therapy, especially when broad-spectrum agents are used, is the disruption of the host's commensal microbiota. By eliminating beneficial bacteria that normally inhabit the gastrointestinal and urogenital tracts, antibiotics remove competitive inhibition and allow opportunistic pathogens to proliferate. The most severe manifestation of this dysbiosis is secondary infection by the spore-forming bacterium Clostridioides difficile (formerly Clostridium difficile), which produces toxins that cause severe pseudomembranous colitis and diarrhea; recurrent cases sometimes require microbiota transplantation therapy to restore normal gut flora.²⁸ Researchers have also investigated the complex, long-term interactions between antibiotic-induced alterations of the microbiome and host immunity, including debated effects on metabolic health and tumorigenesis.

Antimicrobial resistance occurs when bacteria evolve genetic traits that allow them to survive exposure to antibiotics that would normally inhibit or kill them.²⁹ While resistance is an ancient, naturally occurring evolutionary phenomenon among competing soil microbes, the widespread clinical and agricultural deployment of antibiotics has exerted intense selective pressure on bacterial populations worldwide. Bacteria acquire resistance either through spontaneous chromosomal mutations during replication or through horizontal gene transfer, in which resistance genes carried on mobile genetic elements such as plasmids and transposons are exchanged between different bacterial strains and species.

Biochemically, resistant bacteria neutralize antibiotics through several distinct mechanisms. Many species produce specialized enzymes that chemically degrade or modify the drug; the most prominent example is the production of beta-lactamases—including extended-spectrum beta-lactamases (ESBLs) and carbapenemases—which hydrolyze the beta-lactam ring of penicillins, cephalosporins, and carbapenems, rendering them inactive. Other bacteria alter the structural conformation of the antibiotic's intracellular target: methicillin-resistant and beta-lactam-resistant strains modify their penicillin-binding proteins, while vancomycin-resistant enterococci and staphylococci replace the terminal D-alanyl-D-alanine of their peptidoglycan precursors with D-alanyl-D-lactate or D-alanyl-D-serine, sharply reducing the drug's binding affinity. Additionally, bacteria can decrease the uptake of drugs by modifying outer membrane porin channels or actively expel drugs from the cell cytoplasm using membrane-bound efflux pumps. Gram-negative bacteria are particularly adept at combining multiple resistance mechanisms and transmitting them across species.

The global burden of resistant infections represents a severe public health crisis. Globally, antimicrobial resistance was associated with approximately 5 million deaths in 2019, and in the United States alone, more than 2.8 million resistant infections occur annually, resulting in over 35,000 deaths.³⁰ According to the World Health Organization's Global Antibiotic Resistance Surveillance Report 2025—which analyzed more than 23 million bacteriologically confirmed infections reported by 104 countries to the Global Antimicrobial Resistance and Use Surveillance System (GLASS)—1 in 6 laboratory-confirmed common bacterial infections worldwide were resistant to antibiotic treatment in 2023.³¹ Between 2018 and 2023, resistance rates rose in more than 40 percent of monitored pathogen-antibiotic combinations, increasing by an average of 5 to 15 percent annually. Among life-threatening bloodstream infections, more than 40 percent of Escherichia coli isolates and over 55 percent of Klebsiella pneumoniae isolates globally were resistant to third-generation cephalosporins, the standard first-line therapy.³² The burden is distributed unevenly across the globe, disproportionately affecting low- and middle-income nations with weaker healthcare infrastructure: approximately 1 in 3 common bacterial infections are drug-resistant in the WHO Southeast Asian and Eastern Mediterranean regions, and 1 in 5 in the African region, compared to 1 in 10 in Europe.

To slow the spread of resistance and preserve the efficacy of existing medications, public health authorities have instituted antimicrobial stewardship programs across human medicine and agriculture. In 2017, the WHO Expert Committee on Selection and Use of Essential Medicines introduced the Access, Watch, and Reserve (AWaRe) classification framework, updated biennially to guide national prescribing policies and track global consumption across more than 250 antibiotics.³³³⁴ The Access group comprises narrow-spectrum, inexpensive, and safe first- and second-line antibiotics—such as amoxicillin, doxycycline, nitrofurantoin, and metronidazole—that carry a lower risk of driving resistance and should be universally available. The Watch group contains broader-spectrum agents, such as fluoroquinolones, macrolides, and third-generation cephalosporins, which present a higher resistance potential and are recommended only for specific, limited indications. The Reserve group designates last-resort antibiotics saved strictly for life-threatening, multidrug-resistant infections when all other treatments have failed. Under the AWaRe framework, the WHO established a country-level target stipulating that at least 60 percent of all national antibiotic consumption should come from the Access group.

Despite international guidelines, global stewardship efforts face substantial socioeconomic and regulatory hurdles.³⁵ In many low- and middle-income countries, inadequate regulatory enforcement permits the over-the-counter sale of antibiotics without a medical prescription, while a lack of rapid diagnostic testing leads clinicians to prescribe broad-spectrum drugs empirically for viral respiratory illnesses or non-bacterial fevers. Simultaneously, in regions with fragile supply chains, millions of patients suffer from a lack of access to essential first-line Access antibiotics, leading to preventable mortality from otherwise treatable infections.

Beyond human healthcare, the non-medical application of antibacterials is a major driver of resistance. Historically, small cantidades of antibiotics such as chlortetracycline were utilized in the food canning industry for preservation, while vast quantities of medically important antibiotics have been administered to healthy livestock in agriculture to promote rapid growth and prevent disease in crowded conditions. This agricultural overuse selects for resistant bacterial strains—such as fluoroquinolone-resistant Campylobacter and Salmonella—in animal gut flora, which subsequently pass to human populations through the food supply, direct contact, and agricultural runoff into the environment. International "One Health" initiatives seek to coordinate human, veterinary, and environmental policies by restricting the agricultural use of human-critical antibiotics and phasing out growth-promotion practices.

For decades following the mid-twentieth-century golden age, the discovery of novel antibiotic classes stagnated as major pharmaceutical companies exited the field, deterred by the high scientific difficulty of penetrating Gram-negative bacteria and the low financial returns on short-course medications that stewardship programs actively restrict from widespread use.³⁶ To coordinate global research and direct public-private funding toward the most urgent clinical threats, the WHO published its first Bacterial Priority Pathogens List (BPPL) in 2017 and released a major revision in May 2024. Using a multi-criteria decision analysis evaluated by international experts, the 2024 WHO BPPL ranks 24 antibiotic-resistant pathogens across 15 bacterial families into critical, high, and medium priority tiers.³⁷ The critical tier features Gram-negative bacteria resistant to last-resort drugs—specifically carbapenem-resistant Acinetobacter and Enterobacterales, as well as third-generation cephalosporin-resistant Enterobacterales—alongside rifampicin-resistant Mycobacterium tuberculosis. High and medium priority tiers include fluoroquinolone-resistant Salmonella and Shigella, drug-resistant Neisseria gonorrhoeae and Pseudomonas aeruginosa, macrolide-resistant Streptococcus pneumoniae and Group A Streptococci, and penicillin-resistant Group B Streptococci.

Driven by regulatory incentives such as the U.S. Food and Drug Administration's Qualified Infectious Disease Product (QIDP) and Fast Track designations, as well as international research partnerships, the clinical pipeline began yielding significant new treatments in the mid-2020s. One major strategy involves pairing established beta-lactam antibiotics with novel beta-lactamase inhibitors or enhancer molecules to overcome enzymatic resistance. In 2024, the FDA approved the combination of cefepime and enmetazobactam for complicated urinary tract infections (cUTIs) and acute pyelonephritis, offering activity against ESBL-producing Gram-negative bacteria so that clinicians can spare carbapenems. Similarly, in 2024 and 2025, regulatory authorities cleared sulopenem etzadroxil combined with probenecid and the combination of aztreonam and avibactam.

Breakthroughs in novel mechanisms of action and new drug formulations continued through 2025 and 2026. In March 2025, the FDA approved gepotidacin (marketed as Blujepa) for the treatment of uncomplicated urinary tract infections in females aged 12 years and older, marking the first new oral antibiotic class approved for the condition in over two decades. Alongside zoliflodacin (Nuzolvence), gepotidacin has also expanded treatment options for drug-resistant urogenital gonorrhea. In 2026, the FDA cleared two landmark therapies for drug-resistant Gram-negative infections: tebipenem pivoxil (Utebzi), developed by GSK and Spero Therapeutics as the first oral carbapenem antibiotic approved in the United States, and cefepime-zidebactam (Zaynich), an intravenous combination developed by Wockhardt. By simultaneously targeting multiple penicillin-binding proteins and shielding cefepime from beta-lactamase degradation, cefepime-zidebactam achieved an 89.0 percent composite cure rate against complicated urinary tract infections in Phase 3 trials, compared to 68.4 percent for meropenem. Parallel research continues into non-traditional antibacterial therapies, including natural plant and microbial compounds, bacteriophage therapy, and microbiome-modulating treatments designed to combat infections while minimizing selective pressure for resistance.